
Merck and Ridgeback Biotherapeutics provided update on new clinical and non-clinical studies of LAGEVRIOル (molnupiravir)
On Oct. 6, 2022, Merck announced data from two real-world evidence studies evaluating LAGEVRIOル (molnupiravir), an investigational oral antiviral COVID-19 medicine.
In the Clalit observational, retrospective cohort study conducted in Israel , LAGEVRIO was associated with a lower rate of hospitalizations and mortality due to COVID-19 in patients 65 years and above, but not in younger adults.
Tags:
Source: Merck
Credit:
